List is alphabetical by PI last name

Development of an H5N1 Avian Influenza Vaccine for Mucosal Protection
Trainee: Ninaad Lasrado
PI: Dan Barouch
Beth Israel Deaconess Medical Center

Structural basis of coronavirus genomic RNA packaging
Trainee: Yajuan Wang
PI: Bing Chen
Boston Children’s Hospital
Collaborator: Mohsan Saeed
Boston University Chobanian & Avedisian School of Medicine 

Epidemiology of resurgent pandemic cholera in Haiti
Trainee: Yodeline Guillaume
PI: Louise Ivers 
Massachusetts General Hospital
Co-mentor: Molly Franke
Harvard Medical School

Mechanism and evolution of poxvirus immune evasion
Trainee: Samuel Hobbs
PI: Philip Kranzusch
Dana-Farber Cancer Institute

Developing tools to study the pathogenic potential of newly emerging henipaviruses
Trainee: Jarod Herrera
PI: Elke Mühlberger
Co-investigator: Darrell Kotton
Boston University Chobanian & Avedisian School of Medicine 

Discovery of viral-induced cell states in the pediatric nasal mucosa
Trainee: Lillian Juttukonda
PI: Jose Ordovas-Montanes 
Boston Children’s Hospital

High-dimensional profiling and prediction of zoonotic spillover risk in hundreds of picornaviridae
Trainee: Grant Yang
PI: Silvi Rouskin 
Co-mentor: Adam Sychla 
Harvard Medical School

Ultrasensitive Multi-Analyte Detection (MAD) Assays for Predicting Disease Trajectories
Trainees: Louise Hansen & Karan Malhotra
PI: David Walt
Wyss Institute for Biologically Inspired Engineering

Key research resources are infrastructure, platforms, tools, and skilled personnel that enable multiple investigators in the MassCPR to perform multidisciplinary research projects; these awards are denoted by an asterisk*

List is alphabetical by PI last name

Coronavirus cross-reactive monoclonal antibodies from COVID-19 convalescent individuals
Jonathan Abraham (Harvard Medical School)

Prospective profiling of Omicron spike protein evolution
Jonathan Abraham (Harvard Medical School)

Vascular immune response to SARS-Cov-2
Pilar Alcaide (Tufts University)

Systems based Fc-engineering to accelerate therapeutic monoclonal antibody design to COVID-19
Galit Alter (Ragon Institute of MGH, MIT, and Harvard)

System serology antibody profiling of humoral immune responses against variants of concern for SARS-CoV-2
Galit Alter (Ragon Institute of MGH, MIT, and Harvard)

Rapidly conducting clinical trials of novel therapies for SARS-CoV-2 using adaptive design strategies*
Lindsey Baden (Brigham and Women’s Hospital)

The impact of SARS-CoV-2 variants of concern on vaccine-based neutralization
Alejandro Balazs (Massachusetts General Hospital)

Virologic characterization of SARS-CoV-2 variants
Amy Barczak (Massachusetts General Hospital)

Rapidly deployable ventilator splitters to accommodate COVID-19 patient surges
Rebecca Baron (Brigham and Women’s Hospital)

MassCPR biospecimens
Dan Barouch (Beth Israel Deaconess Medical Center)

MassCPR Post-Acute Sequelae of SARS-CoV-2 Infection
Dan Barouch (Beth Israel Deaconess Medical Center)

Protective immunity to SARS-CoV-2 by natural infection and vaccination
Dan Barouch (Beth Israel Deaconess Medical Center)                                 

SARS-CoV-2 variants
Dan Barouch (Beth Israel Deaconess Medical Center)

Support for clinical specimen procurement at Beth Israel Deaconess Medical Center*
Dan Barouch (Beth Israel Deaconess Medical Center)

Novel nanocarbon materials for life-development of distributable textiles that filtrate/neutralize dangerous viruses/bacteria to protect medical professionals and civilians from virus pandemic disease, such as COVID-19
Angela Belcher (Massachusetts Institute of Technology)

Decoding the T cell response to SARS-CoV-2
Christophe Benoist (Harvard Medical School)

MassCPR PASC: Autoimmunity and inflammatory research working group
Nahid Bhadelia (Boston University)

Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)-related dysautonomia
Shamik Battacharyya (Brigham and Women’s Hospital)

COVID Structural biology funding*
Stephen Blacklow (Harvard Medical School)

Surveillance and mathematical modeling of COVID-19 dynamics in Madagascar
Matthew Bonds (Harvard Medical School)

COVID-19 surveillance and forecasting platform
John Brownstein (Boston Children’s Hospital)

Identification of transcriptional pathways and cell states associated with COVID-19 severity in minority and underserved populations
Joshua Campbell (Boston University)

COronavirus Pandemic Epidemiology (COPE)
Andrew Chan (Massachusetts General Hospital)

MassCPR Biospecimen Program
Richelle Charles (Massachusetts General Hospital)

Production of the full-length soluble coronavirus spike (S) protein and ACE2*
Bing Chen (Boston Children’s Hospital)

Structure and function of full-length Spike proteins from SARS-CoV-2 variants
Bing Chen (Boston Children’s Hospital)

Enhancing mRNA-based coronavirus vaccines with lymph node-targeted delivery and neutralizing antibody-inducing adjuvant
Jianzhu Chen (Massachusetts Institute of Technology)

Culture of SARS-CoV-2 variants of interest from the Massachusetts region
John Connor (Boston University)

Staff scientists/veterinary technicians at the NEIDL BSL3/4*
Ronald Corley (Boston University)

HTS for identification and evaluation of efficacy for therapeutics against SARS-CoV-2 infection*
Robert Davey (Boston University)

Evaluating the association between symptoms and COVID-19 test results among health care workers (COVID-HCW)
Michael Dougan (Massachusetts General Hospital)

Analysis of COVID-19 immune responses
Stephen Elledge (Brigham and Women’s Hospital)

Analysis of PASC “long” COVID-19 immune responses
Stephen Elledge (Brigham and Women’s Hospital)

Enhancing detection and treatment of SARS-CoV-2
Stephen Elledge (Brigham and Women’s Hospital)

Wastewater-based epidemiology to rapidly diagnose and map the COVID-19 pandemic
Timothy Erickson (Brigham and Women’s Hospital)

Identifying and targeting host cells and genes crucial in SARS-CoV-2 pathogenesis
Katherine Fitzgerald (University of Massachusetts Medical School)

Modeling SARS-CoV2 variant infections in vivo
Katherine Fitzgerald (University of Massachusetts Medical School)

Evaluating the effectiveness of highly networked CD8+ T cell responses to protect against SARS-CoV-2 variants and sarbecoviruses
Gaurav Gaiha (Massachusetts General Hospital)

Identifying and targeting host cells and genes crucial in SARS-CoV-2 pathogenesis
Robert Finberg (University of Massachusetts Medical School)

A simple and direct antigen rapid test for SARS-CoV-2 infections: ready for scale-up
Lee Gehrke (Massachusetts Institute of Technology)

In vivo studies for SARS-CoV-2 variants
Anthony Griffiths (Boston University)

Evolution of SARS-CoV-2: studying the emergence of variants past and future with population genomics
Bill Hanage (Harvard T.H. Chan School of Public Health)

Molecular and structural analysis of B-cell repertoire in children and adults following infection with SARS-CoV-2
Stephen Harrison (Boston Children’s Hospital and Harvard Medical School)

Senior advisor for clinical partnerships*
Howard Heller (Harvard Medical School)

Characterization of SARS-CoV-2 aerosols and surface contamination produced during respiratory support therapy of COVID-19 patients
Nicholas Hill (Tufts Medical Center)

Companion diagnostics and antivirals for COVID-19 using CRISPR-Cas13
Anna Honko (Boston University)

Contribution to Broad Institute for CLIA COVID-19 testing setup*
Deborah Hung (Broad Institute of MIT and Harvard)

SARS-CoV-2 Variant Dynamics (CoVD)
Karen Jacobson (Boston Medical Center)

Support for clinical specimen procurement at Boston Medical Center*
Karen Jacobson (Boston Medical Center)

PASC-related dysautonomia
Janice John (Cambridge Health Alliance)

Study of biological material collection for research on COVID-19 in subjects receiving care at Tufts Medical Center
Michael Jordan (Tufts Medical Center)

Support for clinical specimen procurement at Tufts Medical Center*
Michael Jordan (Tufts Medical Center)

Open label, randomized controlled Phase 2 study of the use of favipiravir compared to standard of care in hospitalized subjects with COVID-19
Boris Juelg (Massachusetts General Hospital)

Collaborative AI for Covid-19 (CAI4C)
Jayashree Kalpathy-Cramer (Massachusetts General Hospital)

Quantifying relative changes in the analytic performance of three commercially available lateral flow immunochromatographic tests between the SARS-CoV-2 Omicron variant and the Delta variant
Sanjat Kanjilal (Brigham and Women’s Hospital)

Herpesviral recombinant vectors for vaccine vectors and study of coronaviral pathogenesis
David Knipe (Harvard Medical School)

Clinical impact and outcomes of COVID-19 in immunocompromised hosts
Sophia Koo (Brigham and Women’s Hospital)

Human iPSC-derived lung organoids for modeling COVID-19 infection
Darrell Kotton (Boston University)

Integrative metabolomics of PASC through MassCPR
Jessica Lasky-Su (Brigham and Women’s Hospital)

Development of a synthetic biology pipeline for characterization of SARS-CoV-2 viral variants
Jacob Lemieux (Massachusetts General Hospital)

Investigating the emergence of SARS-CoV-2 in special populations, including immunosuppressed persons and patients with vaccine breakthrough, and controls
Jacob Lemieux (Massachusetts General Hospital)

Real-time regional monitoring of SARS-CoV-2 variants
Jacob Lemieux (Massachusetts General Hospital)

MassCPR PASC
Bruce Levy (Brigham and Women’s Hospital)

Rapid discovery and development of an adjuvanted SARS-CoV-2 vaccine optimized for immunogenicity in the elderly
Ofer Levy (Boston Children’s Hospital)

COVID-19 clinical cohort
Jonathan Li (Beth Israel Deaconess Medical Center)

Development of molecular biology tools for studying SARS-CoV-2 variants
Jeremy Luban (University of Massachusetts Medical School)

MassCPR SARS-CoV-2 variants project administration
Jeremy Luban (University of Massachusetts Medical School)

Rapid functional assessment of SARS-CoV-2 variants within the context of the pandemic
Jeremy Luban (University of Massachusetts Medical School)

Differential humoral immune response in children and adults with COVID-19
Richard Malley (Boston Children’s Hospital)

Therapeutic human antibodies against pathogenic coronaviruses that emerge from Southeast Asia including SARS-CoV2
Wayne Marasco (Dana Farber Cancer Institute)

PASC pathobiology: Long-term remodeling after acute infection
Joseph Mizgerd (Boston University)

Peptide: MHCII tetramer reagents for COVID-19 T cell studies
James Moon (Massachusetts General Hospital)

Age-associated development of antibody-mediated cytotoxic immunity to SARS-CoV-2, the virus that causes COVID-19 Disease
Ann Moormann (University of Massachusetts Medical School)

BWH-Critical Care Cardiology Trials Network (CCCTN) multidisciplinary collaborative study on the cardiovascular complications of COVID-19
David Morrow (Brigham and Women’s Hospital)

SARS-CoV-2 infection platforms and development of virological tools to combat the COVID-19 pandemic*
Elke Mühlberger (Boston University)

Large scale, cost-efficient screening and detection of SARS-CoV-2 (COVID-19) in the underserved population
George Murphy (Boston University)

BCG vaccination in healthcare workers for COVID-19
Megan Murray (Harvard Medical School)

Prevention of acute respiratory infection in Taiwanese institutional elderly
Megan Murray (Harvard Medical School)

Infrastructure to design and synthesize novel, broad spectrum inhibitors of SARS-CoV-2 targets, starting with the 3CLpro and PLpro coronavirus proteases*
Mark Namchuk (Harvard Medical School)

Small molecule therapeutics against SARS-CoV-2
Mark Namchuk (Harvard Medical School)

MassCPR PASC: autoimmunity and inflammation research working group
Kerstin Nundel (University of Massachusetts Worcester)

Endothelial-targeted therapy for COVID-19 acute respiratory distress syndrome
Samir Parikh (Beth Israel Deaconess Medical Center)

The mental health consequences of COVID-19 in four high-risk groups
Vikram Patel (Harvard Medical School)

Impaired adaptive immunity and variant generation in severe COVID-19
Shiv Pillai (Massachusetts General Hospital)

MassCPR: Autoimmunity and PASC
Shiv Pillai (Massachusetts General Hospital)

Pulmozyme to improve COVID-19 ARDS outcomes
Benjamin Raby (Boston Children’s Hospital)

Modeling COVID-19 infection with in vitro models of human lung
Jayaraj Rajagopal (Massachusetts General Hospital)

SARS-CoV-2 genomic epidemiology: leveraging insights from ancient DNA
David Reich (Harvard Medical School)

Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) related dysautonomia
Jonathan Rosand (Massachusetts General Hospital)

Development of core data analysis pipelines and a visualization dashboard to for real time SARS-CoV-2 genomic surveillance and epidemiology in the Northeast Region
Pardis Sabeti (Harvard University)                   

MassCPR biospecimens research award: Biobank
Manish Sagar (Boston Medical Center)

MassCPR biospecimens research award: Leadership
Manish Sagar (Boston Medical Center)

Production of the receptor-binding domains (RBDs) from human coronaviruses (CoVs)*
Aaron Schmidt (Ragon Institute of MGH, MIT, and Harvard)

Neutralizing antibody assessment of SARS-CoV-2 variants
Michael Seaman (Beth Israel Deaconess Medical Center)

Optimization of ACE2 models*
Arlene Sharpe (Harvard Medical School)

A molecular study of SARS-CoV-2
Kuang Shen (University of Massachusetts Medical School)

University of Massachusetts COVID-19 biospecimen repository
Karl Simin (University of Massachusetts Medical School Worcester)

Post-Acute Sequelae of SARS-CoV-2 Health Equity Core
Linda Sprague Martinez (Boston University)

A rapid, inexpensive, and versatile SARS-CoV-2 molecular diagnostic test
Michael Springer (Harvard Medical School)

MassCPR Biospecimens Program leadership
Kathryn Stephenson (Beth Israel Deaconess Medical Center)

Rapidly deployable ventilator splitters to accommodate COVID-19 patient surges
Carlo Traverso (Brigham and Women’s Hospital)

Update to the HGHI COVID-19 US Hospital Capacity Model: ICU surge, post-acute care beds, and survey of mechanical ventilator supply
Thomas Tsai (Harvard T.H. Chan School of Public Health) and Ashish Jha (Harvard T.H. Chan School of Public Health)

AAVCOVID: a rapidly deployable SARS-nCoV-2 genetic vaccine for vulnerable populations through academia-industry partnership
Luk Vandenberghe (Massachusetts Eye and Ear)

Unravelling immune and cellular responses associated with Post-Acute COVID-19 syndrome at single-cell resolution
Alexandra-Chloe Villani (Massachusetts General Hospital)

Use of bisphosphonates in the therapy and prophylaxis of COVID-19 infection
Ulrich von Andrian (Harvard Medical School)

A highly networked, exosome-based SARS-CoV-2 vaccine
Bruce Walker (Ragon Institute of MGH, MIT, and Harvard)

Staff scientist at Ragon BSL3*
Bruce Walker (Ragon Institute of MGH, MIT, and Harvard)

Contribution to BWH Diagnostics Accelerator*
David Walt (Brigham and Women’s Hospital)

Detecting the host immune response to SARS-CoV-2 in patient blood using ultra-sensitive assays
David Walt (Brigham and Women’s Hospital)

Immune responses to Post-Acute Sequelae of SARS-CoV-2
David Walt (Brigham and Women’s Hospital)

Ultrasensitive COVID antibody and cytokine assays for MassCPR biospecimens
David Walt (Brigham and Women’s Hospital)

Antibody recognition dynamics of SARS-CoV-2 variants
Duane Wesemann (Brigham and Women’s Hospital)

The human antibody response to SARS-CoV-2
Duane Wesemann (Brigham and Women’s Hospital)

Rapid point-of-care COVID-19 diagnostics using DNA nanoswitches
Wesley Wong (Boston Children’s Hospital)

COVID-19 sample procurement, processing, storage, and sharing/distribution*
Xu Yu (Ragon Institue of MGH, MIT, and Harvard), Jonathan Li (Brigham and Women’s Hospital), and Lindsey Baden (Brigham and Women’s Hospital)

Development of a point-of-care diagnostic for COVID-19
Feng Zhang (Massachusetts Institute of Technology)

Quantify the role of social distancing in shaping the COVID-19 curve: incorporating adaptive behavior and preference shifts in epidemiological models using novel Big Data in 344 Chinese cities
Siqi Zheng (Massachusetts Institute of Technology)

Access to large quantities of purified SARS-CoV-2 proteins and to laboratory models of key steps in the SAR-CoV-2 lifecycle have been essential to the research of many MassCPR investigators and for testing and characterizing potential anti-viral therapies.

Chen and colleagues (BCH) produced soluble SARS-CoV-2 spike (S) trimer and soluble human ACE2 receptor domains in milligram quantities, and generated stable cell lines for large-scale production of these recombinant proteins to support research by MassCPR investigators. Cryo-EM structures of full-length S proteins derived from several viral variants were determined; these will help guide development of improved vaccines, therapeutics, and diagnostics.

Schmidt and colleagues (HMS) produced and purified large quantities of the receptor binding domain (RBD) of the surface-exposed SARS-CoV-2 S protein. This was distributed to more than 40 different laboratories and hospitals worldwide for diverse projects, including projects focused on developing COVID diagnostics, assaying immune responses from vaccine candidates in clinical trials, and elucidating mechanisms of pathogenesis for SARS-CoV-2.

Namchuk and colleagues (HMS) developed high-throughput enzyme assays for the SARS-CoV-2 proteases Mpro and PLpro. Strategies for structure-enabled design of peptidomimetic inhibitors of Mpro and PLpro were also developed; several novel protease inhibitor candidates are being further pursued as possible anti-COVID therapeutics.

Sharpe and colleagues (HMS) set up a breeding colony of human K18 hACE2 transgenic mice and shared the mice with MassCPR investigators for studies of SARS CoV-2 infection. The availability of this strain was limited at the beginning of the pandemic and it was helpful to have a local colony. Work was also done to optimize use of the mouse strain for in vivo studies of SARS-CoV-2 pathogenesis, vaccines, and therapeutics in collaboration with investigators Davey, Corley, and others at the National Emerging Infectious Disease Laboratories (NEIDL) at Boston University.

Validation studies using infection models are important for the development of antiviral countermeasures. SARS-CoV-2 is classified as a biosafety level 3 (BSL-3) pathogen. To facilitate studies with live virus, MassCPR provided virology support to members of the Massachusetts research community who did not otherwise have access to high-containment laboratories. MassCPR support for BSL-3 resources at the Ragon Institute (Walker) supported cell-based virus assays for approximately 10 laboratories, and provided training for several new BSL-3 users. PIs Davey and Muhlberger and colleagues, working at the National Emerging Infectious Disease Laboratories (NEIDL) at Boston University, provided tissue culture cell-based and primary cell-based assays, as well as mouse model assays, for detection of viral infection and replication. These were used to screen candidate small molecule therapeutics directed against SARS-CoV-2 and to study host response to SAR-CoV-2 infection.

MassCPR made an early contribution to the Broad Institute (Hung) that facilitated set-up of a CLIA-compliant COVID-19 testing resource and enabled successful application for FDA Emergency Use Authorization for a Broad-developed clinical diagnostic test. Once established, the Broad testing service provided fee-for-service testing for nursing homes, hospitals, community health centers, underserved communities, schools, and employers throughout Massachusetts. Funding to the BWH Diagnostics Accelerator (Walt) supported work to establish an efficient pipeline for standardized evaluation of COVID-19 diagnostic tests, both in the lab and in field studies. This has allowed for a rapid comparison of test sensitivity, specificity, and reproducibility across multiple PCR and rapid antigen tests.

Immediately following its establishment, MassCPR had the foresight to prioritize coordinating the collection and distribution of COVID-19 patient biospecimens across its consortium. MassCPR directly supported establishment of patient COVID-19 patient cohorts and biobanking efforts at BIDMC (Barouch), Boston Medical Center (Jacobson), Tufts Medical Center (Jordan), BWH (Li), and MGH and the Ragon Institute (Yu). The MassCPR Sample Access Accelerator Committee (SAAC), comprised of 17 representative experts from each of its clinical institutions and chaired by Heller (MGH) and Walt (BWH), established a common framework for collecting, storing, and distributing COVID-19 clinical biospecimens in a transparent, fair, and prioritized manner. Through mid-2021, more than 88,000 biosamples from almost 1,700 subjects were collected and stored. Of those, slightly more than 4,000 were distributed via 61 independent requests from 13 research institutions.

Baden and colleagues (BWH) leveraged seed funding from MassCPR and used adaptive trial designs to develop clinical trials to study novel, potentially active antiviral and immunomodulatory therapies against SARS-CoV-2. Several trials were designed and implemented, such as one that supported the development of high SARS-CoV-2 titer convalescent plasma. From this work, an overarching adaptive clinical trial study design platform was created to rapidly assess novel compounds in patients with COVID-19. The trials were further supported with funding from philanthropy and collaborative grants from industry and the NIH.